Case report: Efficacy of immune checkpoint inhibitors for high tumour mutational burden malignant phyllodes tumours of the breast as revealed by comprehensive genomic profiling

High tumour mutational burden (TMB-high), identified through comprehensive genomic profiling (CGP), is a biomarker that predicts the efficacy of immune checkpoint inhibitors. CGP testing is recommended for rare cancers with limited effective treatment options. Here, we provide the first report of a...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Hiroo Katsuya, Haruhiko Sano, Haruna Sano, Tatsuya Mihashi, Chiho Nakashima, Keita Kai, Shinya Kimura
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2025-02-01
Seria:	Frontiers in Immunology
Hasła przedmiotowe:	immune checkpoint inhibitor (ICI) tumour mutational burden (TMB) malignant phyllodes tumor of the breast comprehensive genomic profiling (CGP) microsatellite instability
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1549452/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!